IDH1 and IDH2 are mutated in >70% of lower-grade gliomas (grades II and III), in some glioblastomas, and ∼20% of AML, but also in cholangiocarcinoma, chondrosarcoma, and in other cases of different tumor types [92]. Here, IDH1 is linked to acute myeloid leukemia.